Sotera Health Company (SHC)
NASDAQ: SHC · Real-Time Price · USD
12.80
+0.06 (0.47%)
At close: May 16, 2025, 4:00 PM
12.80
0.00 (0.00%)
After-hours: May 16, 2025, 5:10 PM EDT
Sotera Health Company Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Sotera Health Company stock ranges from a low of $12 to a high of $20. The average analyst price target of $15.8 forecasts a 23.44% increase in the stock price over the next year.
Price Target: $15.80 (+23.44%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Sotera Health Company stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $14 → $17 | Hold → Strong Buy | Upgrades | $14 → $17 | +32.81% | May 5, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $15 → $13 | Hold | Maintains | $15 → $13 | +1.56% | Apr 23, 2025 |
| Barclays | Barclays | Buy Maintains $16 → $12 | Buy | Maintains | $16 → $12 | -6.25% | Apr 10, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $16 | Buy | Maintains | $17 → $16 | +25.00% | Feb 28, 2025 |
| Barclays | Barclays | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +32.81% | Feb 18, 2025 |
Financial Forecast
Revenue This Year
1.15B
from 1.10B
Increased by 4.87%
Revenue Next Year
1.22B
from 1.15B
Increased by 5.98%
EPS This Year
0.75
from 0.16
Increased by 377.73%
EPS Next Year
0.85
from 0.75
Increased by 13.53%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 1.2B | 1.3B | 1.4B | |
| Avg | 1.2B | 1.2B | 1.3B | |
| Low | 1.1B | 1.2B | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 10.0% | 11.4% | 11.6% | |
| Avg | 4.9% | 6.0% | 6.4% | |
| Low | 0.9% | 1.7% | 1.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 0.82 | 0.93 | 1.03 | |
| Avg | 0.75 | 0.85 | 0.95 | |
| Low | 0.71 | 0.79 | 0.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 422.3% | 24.3% | 21.0% | |
| Avg | 377.7% | 13.5% | 11.4% | |
| Low | 350.0% | 6.0% | 3.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.